Imatinib discontinuation for hypereosinophilic syndrome harboring the <i>FIP1L1-PDGFRA</i> transcript

Helbig, Grzegorz; Soja, Anna; Świderska, Alina; Hus, Marek; Kyrcz‐Krzemień, Sławomira

doi:10.3109/10428194.2015.1065983

Cited by 9 publications

(9 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Helbig et al discontinued imatinib in 7 patients after a median of 79.2 months receiving imatinib and a median of 55.2 months in CMR. 6 Three patients experienced a molecular relapse within 6 months, and 4 patients remained in CMR for a median of 28 months. Relapse-free survival was 57% at 12 months.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

et al. 2020

View full text Add to dashboard Cite

FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) are exquisitely sensitive to imatinib. Almost all patients achieve a complete molecular remission (CMR) by nested reverse transcription polymerase chain reaction, which can be maintained with low-dose imatinib (eg, 3 × 100 mg/wk). Because imatinib can be safely stopped in a substantial proportion of patients with BCR-ABL1–positive CML, we sought to analyze the clinical and molecular follow-up of 12 FIP1L1-PDGFRA–positive patients with MLN-eo in chronic phase who discontinued imatinib after achievement of a CMR. Median time of treatment and median time of CMR before imatinib discontinuation (last dose at 3 × 100 mg/wk, n = 8; or 100 mg/d, n = 4) were 80 (range, 43-175) and 66 (range, 37-174) months, respectively. A molecular relapse was observed in 4 patients after 10, 22 (n = 2), and 24 months. A second CMR was achieved in 3 patients after 3, 4, and 21 months. Eight patients (62%) are in ongoing CMR (median, 17 months; range, 3-71 months). Molecular relapse-free survival was 91% at 12 months and 65% at 24 months. No significant differences (eg, dose and duration of imatinib treatment or duration of CMR before imatinib discontinuation) were identified between patients with and without molecular relapse. Our data demonstrate that imatinib can be safely stopped in FIP1L1-PDGFRA–positive MLN-eo because of a high treatment-free remission at 12 and 24 months and because most patients achieve a rapid second CMR after restart of imatinib.

show abstract

Section: Resultsmentioning

confidence: 99%

“…3 Analogous to modern management of chronic myeloid leukemia (CML), 4,5 hematologists and patients frequently ask for the option to safely stop imatinib once they have achieved sustained CMR. 2,[6][7][8][9]…”

Section: Introductionmentioning

confidence: 99%

Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Indeed, two recent studies reported that around 50% of the patients with PDGFRA translocation who achieved complete molecular remission with imatinib maintained it after stopping treatment [7,8]. Importantly, all the patients who relapsed regained a complete response after restarting imatinib [5,7,8].…”

mentioning

confidence: 99%

Circulating aberrant plasma cells allow risk stratification of patients with myeloma

et al. 2016

View full text Add to dashboard Cite

“…While in a first report by Klion et al all the 4 patients who stopped imatinib relapsed [5], another experience demonstrated that some patients can remain off therapy without losing their response [6]. Indeed, two recent studies reported that around 50% of the patients with PDGFRA translocation who achieved complete molecular remission with imatinib maintained it after stopping treatment [7,8]. Importantly, all the patients who relapsed regained a complete response after restarting imatinib [5,7,8].…”

mentioning

confidence: 99%

mentioning

confidence: 99%

Long‐term therapy‐free remission in a patient with platelet‐derived growth factor receptor beta‐rearranged myeloproliferative neoplasm

et al. 2016

View full text Add to dashboard Cite

Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript

Cited by 9 publications

References 11 publications

Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

Treatment-free remission in FIP1L1-PDGFRA–positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation

Circulating aberrant plasma cells allow risk stratification of patients with myeloma

Long‐term therapy‐free remission in a patient with platelet‐derived growth factor receptor beta‐rearranged myeloproliferative neoplasm

Contact Info

Product

Resources

About